Hims & Hers Health (HIMS) Capital Expenditures (2020 - 2026)
Hims & Hers Health (HIMS) reported Capital Expenditures of $29.8 million for Q1 2026, down 46.06% on a YoY basis from $55.3 million in Q1 2025, and up 357.34% sequentially from -$11.6 million in Q4 2025.
Hims & Hers Health (HIMS) Capital Expenditures (2020 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 7 years of Capital Expenditures data on file, last reported at $29.8 million in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 46.06% year-over-year to $29.8 million; the trailing twelve-month figure through Mar 2026 stood at -$239000.0 (down 100.43% YoY), and the FY2025 full-year result was $25.2 million, up 44978.57% from the prior year.
- Capital Expenditures improved to $29.8 million in Q1 2026, from -$11.6 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $55.3 million in Q1 2025 to a low of -$47.4 million in Q2 2025.
- A 5-year average of $4.8 million and a median of $1.3 million in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures plunged 262.43% in 2024 and jumped 117617.02% in 2025, its largest moves.
- Tracing HIMS's Capital Expenditures over 5 years: stood at -$17000.0 in 2022, then jumped by 61952.94% to $10.5 million in 2023, then sank by 262.43% to -$17.1 million in 2024, then jumped by 32.1% to -$11.6 million in 2025, then surged by 357.34% to $29.8 million in 2026.
- Business Quant data shows HIMS's Capital Expenditures at $29.8 million in Q1 2026, -$11.6 million in Q4 2025, and $28.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 99.60 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | 29.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.84 Mn |
| Mar 31, 2026 | 29.84 Mn |
| Dec 31, 2025 | -11.60 Mn |
| Dec 31, 2025 | -11.60 Mn |
| Sep 30, 2025 | 28.88 Mn |
| Sep 30, 2025 | 28.88 Mn |
| Jun 30, 2025 | -47.37 Mn |
| Jun 30, 2025 | -47.37 Mn |
| Mar 31, 2025 | 55.33 Mn |
| Mar 31, 2025 | 55.33 Mn |
| Dec 31, 2024 | -17.08 Mn |
| Dec 31, 2024 | -17.08 Mn |
| Sep 30, 2024 | 17.09 Mn |
| Sep 30, 2024 | 17.09 Mn |
| Mar 31, 2024 | 47,000.00 |
| Mar 31, 2024 | 47,000.00 |
| Dec 31, 2023 | 10.52 Mn |
| Dec 31, 2023 | 10.52 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Sep 30, 2023 | 1.39 Mn |